Join us in an engaging webinar as Adrian Simpson, from HDT Bio, delves into the intriguing science behind their novel emulsion platform, known as LION. Discover how this cutting-edge platform enables ...

SEATTLE, Jan. 15, 2025 /PRNewswire/ -- MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid ...

SEATTLE, Aug. 7, 2024 /PRNewswire/ -- HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, today announced the publication demonstrating the potential for ...

SEATTLE, March 24, 2023 /PRNewswire/ -- HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, today announced the peer-reviewed publication of preclinical data ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

SEATTLE, May 21, 2026 /PRNewswire/ -- HDT Bio, a clinical-stage biotechnology company based in Seattle, Washington, today announced that it received the Medical CBRN Defense Consortium (MCDC) ...

HDT Bio's work focuses on infectious disease and oncology vaccines and therapeutics through early-stage collaborations with partners worldwide. The company's vaccine platforms combine formulation and ...

Seattle startup HDT Bio will develop a nasal spray designed to counteract a wide range of respiratory viruses with a… Read More Seattle vaccine company HDT Bio is seeking nearly $1 billion in a new ...